IPHA Innate Pharma S.A.
Healthcare$1.72-6.01%ClosedMarket Cap: $161.5M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
-6.80
P/S
54.38
EV/EBITDA
-2.61
DCF Value
$-0.08
FCF Yield
-34.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
100.0%
Operating Margin
-2058.0%
Net Margin
-1764.5%
ROE
593.9%
ROA
-78.4%
ROIC
-155.5%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 null | $-2.1M | -889.9% | $-28.0M | $-27.6M | $— | — |
| FY null | $2.8M | 100.0% | $-53.4M | $-49.2M | $— | — |
| Q2 null | $4.9M | -322.2% | $-25.4M | $-21.3M | $— | — |
| Q4 null | $276.0K | 10634.8% | $-25.3M | $-24.7M | $— | — |
| FY null | $12.6M | 100.0% | $-51.6M | $-49.5M | $— | — |
| Q2 null | $12.3M | -135.5% | $-26.3M | $-24.8M | $— | — |
| Q4 null | $16.6M | -18.9% | $-7.4M | $-9.3M | $— | — |
| FY null | $51.9M | 10.8% | $-12.7M | $-7.6M | $— | — |
| Q2 null | $35.3M | 55.5% | $-5.3M | $1.7M | $— | — |
| Q4 null | $8.3M | -60.7% | $-28.8M | $-64.4M | $— | — |
| FY null | $57.7M | 10.4% | $-57.4M | $-58.1M | $— | — |
| Q2 null | $41.3M | 69.8% | $4.2M | $6.3M | $— | — |